NZ544079A - Biologically active peptides consisting of SEQ ID 4 that modulate immune activity and growth of cancer - Google Patents

Biologically active peptides consisting of SEQ ID 4 that modulate immune activity and growth of cancer

Info

Publication number
NZ544079A
NZ544079A NZ544079A NZ54407902A NZ544079A NZ 544079 A NZ544079 A NZ 544079A NZ 544079 A NZ544079 A NZ 544079A NZ 54407902 A NZ54407902 A NZ 54407902A NZ 544079 A NZ544079 A NZ 544079A
Authority
NZ
New Zealand
Prior art keywords
peptide
group
prt
peptides
sus scrofa
Prior art date
Application number
NZ544079A
Other languages
English (en)
Inventor
Wai Ming Wong
Kong Lam
Original Assignee
Cms Peptides Patent Holding Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cms Peptides Patent Holding Co filed Critical Cms Peptides Patent Holding Co
Publication of NZ544079A publication Critical patent/NZ544079A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ544079A 2001-07-13 2002-07-11 Biologically active peptides consisting of SEQ ID 4 that modulate immune activity and growth of cancer NZ544079A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90449201A 2001-07-13 2001-07-13

Publications (1)

Publication Number Publication Date
NZ544079A true NZ544079A (en) 2007-10-26

Family

ID=25419251

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ544079A NZ544079A (en) 2001-07-13 2002-07-11 Biologically active peptides consisting of SEQ ID 4 that modulate immune activity and growth of cancer
NZ529879A NZ529879A (en) 2001-07-13 2002-07-11 Biologically active peptides such as YSL and their use in pharmaceuticals
NZ553507A NZ553507A (en) 2001-07-13 2002-07-11 Biologically active peptides

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ529879A NZ529879A (en) 2001-07-13 2002-07-11 Biologically active peptides such as YSL and their use in pharmaceuticals
NZ553507A NZ553507A (en) 2001-07-13 2002-07-11 Biologically active peptides

Country Status (23)

Country Link
EP (3) EP1478659B1 (enExample)
JP (3) JP4213581B2 (enExample)
KR (2) KR100889993B1 (enExample)
AT (2) ATE414099T1 (enExample)
AU (1) AU2002319423B2 (enExample)
BR (1) BR0210252A (enExample)
CA (2) CA2452417C (enExample)
DE (2) DE60236330D1 (enExample)
DK (2) DK1790655T3 (enExample)
ES (2) ES2316586T3 (enExample)
IL (2) IL159827A0 (enExample)
MX (1) MXPA03011190A (enExample)
MY (1) MY138219A (enExample)
NO (2) NO332061B1 (enExample)
NZ (3) NZ544079A (enExample)
PL (2) PL211884B1 (enExample)
PT (2) PT1790655E (enExample)
RU (2) RU2425053C2 (enExample)
SA (1) SA04240478B1 (enExample)
SG (2) SG185137A1 (enExample)
UA (1) UA83989C2 (enExample)
WO (1) WO2003006492A2 (enExample)
ZA (2) ZA200401108B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1213062C (zh) 2001-07-13 2005-08-03 一泰医药研究（深圳）有限公司 序列号13的生物活性肽
AU2003285258A1 (en) * 2002-12-18 2004-07-09 Pepharm R & D Limited Biologically active peptide conjugates
TWI322815B (en) * 2003-06-26 2010-04-01 Cms Peptides Patent Holding Company Ltd Biologically active peptide comprising tyrosyl-seryl-valine (ysv)
TWI353252B (en) 2004-04-28 2011-12-01 Cms Peptides Patent Holding Company Ltd Biologically active peptide vapeehptllteaplnpk der
CN1799623B (zh) * 2005-01-05 2011-01-26 康哲医药研究(深圳)有限公司 生物活性肽在制备用于防治关节炎的药物中的用途
KR101381337B1 (ko) * 2005-07-26 2014-04-11 씨엠에스 펩티드 패턴트 홀딩 컴퍼니 리미티드 신규한 생물학적 활성 펩티드 및 그의 신규한 용도
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
RU2429005C1 (ru) * 2010-10-07 2011-09-20 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН Способ стимуляции противоопухолевой активности цитотоксических эффекторов иммунной системы
RU2615908C1 (ru) * 2016-05-16 2017-04-11 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ моделирования лимфогенного и гематогенного метастазирования мышиной меланомы В16 у белых нелинейных крыс
TWI890506B (zh) * 2024-06-27 2025-07-11 開曼群島商味丹國際（控股）有限公司 具有抑制ace活性之胜肽及其組合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242821A (en) 1989-07-10 1993-09-07 Valio, Finnish Co-Operative Dairies' Association Lactococcus promoter and signal sequences for expression in bacteria
IT1231156B (it) 1989-07-19 1991-11-19 Eniricerche Spa Espressione e secrezione di interleuchina 1 beta umana matura in bacillus subtilis e mezzi e metodi per il suo ottenimento.
WO1991009613A1 (en) * 1989-12-22 1991-07-11 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Synthetic peptides as modulators of functional responses of intact cells
US5556744A (en) * 1992-05-29 1996-09-17 The Trustees Of The University Of Pennsylvania Methods and compositions for diagnosing and treating certain HIV infected patients
WO1994029450A2 (en) 1993-06-15 1994-12-22 E.I. Du Pont De Nemours And Company Novel, recombinantly produced spider silk analogs
JP3286420B2 (ja) 1993-09-28 2002-05-27 株式会社ユニシアジェックス 内燃機関の吸排気弁駆動制御装置
AU2631695A (en) 1994-06-17 1996-01-15 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Method for introduction of genetic material into microorganisms and transformants obtained therewith
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US5958416A (en) * 1994-12-16 1999-09-28 Regents Of The University Of Minnesota Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
IL115199A (en) 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
EP0867450B1 (en) 1995-10-24 2004-08-11 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute TFPI-related Peptides which inhibit growth of smooth muscle cells
GB9606016D0 (en) * 1996-03-22 1996-05-22 Smithkline Beecham Plc Novel use
US5861483A (en) * 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
SE9603468D0 (sv) * 1996-09-23 1996-09-23 Astra Ab New compounds
GB9710762D0 (en) * 1997-05-23 1997-07-23 Cancer Res Inst Royal Binding complexes
EP1015612B1 (en) 1997-05-27 2005-01-26 Hanil Synthetic Fiber Co., Ltd. Process for preparing recombinant proteins using highly efficient expression vector from saccharomyces cerevisiae
KR19990024297A (ko) 1997-08-07 1999-04-06 오종석 인체 구강내 치태형성을 억제하는 신규한 유산균
US6100388A (en) 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
US6245427B1 (en) 1998-07-06 2001-06-12 DüZGüNES NEJAT Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
CA2341157A1 (en) * 1998-08-31 2000-03-09 University Of Washington Stable isotope metabolic labeling for analysis of biopolymers
US6413530B1 (en) * 1999-04-21 2002-07-02 University Of Florida Research Foundation, Inc. Pesticidal peptides
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
WO2001032853A1 (en) * 1999-10-29 2001-05-10 Institute For Applied Biomedicine B cell clonal toxins and methods for using the same

Also Published As

Publication number Publication date
DK1478659T3 (da) 2009-01-05
WO2003006492A3 (en) 2003-12-31
DE60229883D1 (de) 2008-12-24
UA83989C2 (ru) 2008-09-10
NO332061B1 (no) 2012-06-11
HK1098767A1 (en) 2007-07-27
NO20073914L (no) 2004-03-10
EP1947109A3 (en) 2008-10-01
KR100889993B1 (ko) 2009-03-25
SG185137A1 (en) 2012-11-29
DE60236330D1 (de) 2010-06-17
WO2003006492A2 (en) 2003-01-23
IL159827A0 (en) 2004-06-20
EP1790655A2 (en) 2007-05-30
NO20040134L (no) 2004-03-10
ES2316586T3 (es) 2009-04-16
AU2002319423B2 (en) 2008-02-14
HK1066552A1 (en) 2005-03-24
PT1478659E (pt) 2009-01-02
NZ553507A (en) 2008-07-31
ES2345842T3 (es) 2010-10-04
EP1478659A2 (en) 2004-11-24
MY138219A (en) 2009-05-29
CA2452417C (en) 2013-08-20
KR20040019058A (ko) 2004-03-04
DK1790655T3 (da) 2010-08-23
EP1478659B1 (en) 2008-11-12
ATE466871T1 (de) 2010-05-15
JP4316651B2 (ja) 2009-08-19
RU2305107C2 (ru) 2007-08-27
EP1790655B1 (en) 2010-05-05
PL211884B1 (pl) 2012-07-31
EP1790655A3 (en) 2007-10-10
CA2707767C (en) 2013-09-03
JP2008263993A (ja) 2008-11-06
ZA200401108B (en) 2006-05-31
RU2007108896A (ru) 2008-09-20
CA2452417A1 (en) 2003-01-23
JP2004533846A (ja) 2004-11-11
KR20070070258A (ko) 2007-07-03
PT1790655E (pt) 2010-07-09
JP4213581B2 (ja) 2009-01-21
IL184227A (en) 2010-06-16
MXPA03011190A (es) 2004-10-28
NZ529879A (en) 2007-12-21
ZA200509838B (en) 2007-11-28
RU2425053C2 (ru) 2011-07-27
RU2004104335A (ru) 2005-03-27
KR100889992B1 (ko) 2009-03-25
JP2007312785A (ja) 2007-12-06
ATE414099T1 (de) 2008-11-15
EP1947109A2 (en) 2008-07-23
BR0210252A (pt) 2004-09-14
PL208666B1 (pl) 2011-05-31
CA2707767A1 (en) 2003-01-23
IL184227A0 (en) 2007-10-31
SA04240478B1 (ar) 2007-07-31
SG142165A1 (en) 2008-05-28
PL368059A1 (en) 2005-03-21

Similar Documents

Publication Publication Date Title
IL184227A (en) Biologically active peptides, genetic vector, micro-organism comprising a nucleotide sequence encoding said peptide, pharmaceutical compositions comprising said peptide, method for preparing said pharmaceutical compositions, and use thereof
US20080293641A1 (en) Biologically active peptides
AU2002319423A1 (en) Biologically active peptides
US20060167229A1 (en) Biologically active peptide conjugates
AU2007211899B2 (en) Biologically active peptides
US7718764B2 (en) Biologically active peptide VAPEEHPTLLTEAPLNPK derivatives
HK1098767B (en) Biologically active peptides
HK1066552B (en) Biologically active peptides

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: CMS PEPTIDES PATENT HOLDING COMPANY LIMITED, VG

Free format text: OLD OWNER(S): PEPHARM R AND D LIMITED

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed